Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07543055 | A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread | PHASE1 | NOT YET_RECRUITING | 36 | — | — | Jun 1, 2026 | Mar 20, 2031 | May 29, 2026 | - | — |
| Arm | Type | Description |
|---|---|---|
| BPX-601 monotherapy | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BPX-601 | GENETIC | Administered per protocol |
Key Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of hormone-refractory adenocarcinoma of the prostate without pure small cell carcinoma 2. Metastatic, Castration-Resistant Prostate Cancer (mCRPC) with PSA value at screening ≥4 ng/mL that has progressed within 6 months ...